Last updated on April 2020

EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment


Brief description of study

The aim of this adaptive Phase 3 trial is to show a statistically significant superiority of EndoTAG-1 in combination with gemcitabine compared to gemcitabine monotherapy in patients with locally advanced/metastatic pancreatic cancer after FOLFIRINOX failure.

Clinical Study Identifier: NCT03126435

Find a site near you

Start Over

Karmanos Cancer Institute

Detroit, MI United States
  Connect »

Henry Ford Hospital

Detroit, MI United States
  Connect »

Charleston Cancer Center

North Charleston, SC United States
  Connect »

Renovatioclinical

The Woodlands, TX United States
  Connect »

University of Virginia Hospital

Charlottesville, VA United States
  Connect »

CHU Angers

Angers, France
  Connect »

CHRU - Besan on

Besançon, France
  Connect »

La Timone

Marseille, France
  Connect »

Rabin MC

Petach Tikva, Israel
  Connect »

National Cancer Center

Goyang-si, Korea, Republic of
  Connect »

Inha University Hospital

Incheon-si, Korea, Republic of
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Severance Hospital

Seoul, Korea, Republic of
  Connect »

Ajou University Hospital

Suwon, Korea, Republic of
  Connect »

Oncolab

Craiova, Romania
  Connect »

CHRU - Besan on

Besançon, France
  Connect »

Oncohelp

Timisoara, Romania
  Connect »

E-Da Hospital

Kaohsiung, Taiwan
  Connect »

Emory University Hospital

Atlanta, GA United States
  Connect »

CHRU - Besan on

Besançon, France
  Connect »

CHA Bundang Medical Center

Seongnam, Korea, Republic of
  Connect »

CHRU - Besan on

Besançon, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.